We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Component-controlled synthesis and assembly of Cu-Pd nanocrystals on graphene for oxygen reduction reaction.
ACS Applied Materials & Interfaces 2015 March 12
Exploring low-cost, high-activity, and long-durability hybrid electrocatalysts for cathodic oxygen reduction reaction (ORR) is vital to advance fuel cells technologies. In this paper, a series of graphene (G)-CuxPdy (Cu4Pd, Cu3Pd, CuPd, CuPd3, CuPd4) nanocomposites (G-CuxPdy NCPs) is obtained by assembly of CuxPdy alloy nanocrystals (NCs) with controlled component ratios on G nanosheets using the "dispersing-mixing-vaporizing solvent" strategy and used as electrocatalysts for ORR. Compared with pure CuxPdy NCs, greatly enhanced interfacial electron transfer dynamics are observed in G-CuxPdy NCPs, which show a strong correlation with the alloy compositions of the NCPs. The electrocatalytic experiments in alkaline solution reveal that the ORR activities of those G-CuxPdy NCPs are also strongly dependent on alloy components and exhibit a double-volcano feature with variations of alloy components. Among them, G-Cu3Pd NCPs possess the highest electrocatalytic activity, which is much better than some reported electrocatalysts and commercial Pd/C catalyst and close to Pt/C catalyst. By correlating the Pd 3d binding energies and the sizes of CuxPdy NCs with the mass-specific activities of G-CuxPdy NCPs and considering the interfacial electron transfer dynamics, the best catalytic activity of G-Cu3Pd NCPs may result from the unique electronic structure and the smallest size of Cu3Pd NCs as well as the strong synergistic effect between G and Cu3Pd NCs. Moreover, the durability of G-Cu3Pd NCPs is superior to that of Pt/C catalyst, indicating that they are promising cathodic electrocatalysts for using in alkaline fuel cells.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app